Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Ocean Biomedical, Inc. (NASDAQ:OCEA) announced Wednesday that it received a decision from the Nasdaq Listing and Hearing Review Council affirming the delisting of its securities from The Nasdaq Stock Market. The company disclosed the development in a press release and SEC filing.
According to the filing, the Nasdaq Hearings Panel had previously decided on April 22, 2025, to delist the company’s shares and suspend trading, effective at the opening of business on April 24, 2025. Ocean Biomedical appealed this decision to the Listing Council.
On July 17, 2025, the Listing Council upheld the Panel’s original decision, confirming the delisting of Ocean Biomedical’s securities from Nasdaq. The company stated that the Listing Council’s decision affirms Nasdaq’s delist decision letter dated April 22, 2025.
Ocean Biomedical is incorporated in Delaware and is classified under pharmaceutical preparations. The company’s principal executive offices are located in Providence, Rhode Island.
The information in this article is based on a press release and a filing with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.